IL13RA2 and prostate carcinoma: Additionally, a limited number of CSC markers are currently available but their biological function needs to be fully characterized, such as CSPG4 in multiple cancer types [76], EGFRvIII [77] and IL13Rα2 [78] in gliomas, and EpCAM in prostate cancer [79].